Patents by Inventor Suoming Zhang

Suoming Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100152103
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I and the pharmaceutically salts thereof. The variables are defined herein. Certain compounds of Formula I are useful as antiviral agents. 4-amino-4-oxobutanoyl peptide cyclic analogues as disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide cyclic analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptide cyclic analogue as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptide cyclic analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in patients.
    Type: Application
    Filed: December 10, 2009
    Publication date: June 17, 2010
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Avinash Phadke, Xiangzhu Wang, Godwin Pais, Akihiro Hashimoto, Venkat Gadhachanda, Dawei Chen, Atul Agarwal, Suoming Zhang, Cuixian Liu, Shouming Li, Milind Deshpande
  • Publication number: 20100124545
    Abstract: The invention provides cyclic carboxamide compounds and analogues thereof of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents.
    Type: Application
    Filed: November 20, 2009
    Publication date: May 20, 2010
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Suoming Zhang, Avinash Phadke, Milind Deshpande, Venkat Gadhachanda
  • Publication number: 20090304605
    Abstract: The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II where A is a group of the formula: and the variables X, Y, R, and R1 to R7 are described herein. These compounds are prodrugs of compounds useful as inhibitors of viral replication. Compositions containing such compounds, and methods of treating viral infections with these compounds, as well as to processes and intermediates useful for preparing such compounds are also provided by the invention.
    Type: Application
    Filed: June 5, 2009
    Publication date: December 10, 2009
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Cuixan Liu, Avinash Phadke, Xiangzhu Wang, Suoming Zhang
  • Publication number: 20090048297
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
    Type: Application
    Filed: July 13, 2007
    Publication date: February 19, 2009
    Applicant: ACHILLION PHARMACEUTICALS
    Inventors: Avinash Phadke, Xiangzhu Wang, Suoming Zhang, Atul Agarwal
  • Publication number: 20070212297
    Abstract: Amino methyl imidazoles of Formula I are provided: wherein R, R1, R2, R3, R4, R5, and R6 are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. Additionally, this invention provides labeled amino methyl imidazoles compounds, which are useful as probes for the localization of C5a receptors.
    Type: Application
    Filed: December 22, 2006
    Publication date: September 13, 2007
    Inventors: Andrew Thurkauf, He Zhao, Suoming Zhang, Yang Gao
  • Publication number: 20070208048
    Abstract: The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula where the ring system represented by is a 5 membered heteroaryl ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen provided that the 5 membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heteroaryl ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar1, Ar2, R, R1, R2, R3, R4, R5, R6, y and z are defined herein Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors.
    Type: Application
    Filed: March 1, 2007
    Publication date: September 6, 2007
    Inventors: George Luke, George Maynard, Scott Mitchell, Andrew Thurkauf, Linghong Xie, LuYan Zhang, Suoming Zhang, He Zhao, Bertrand Chenard, Yang Gao, Bingsong Han, Xiao He
  • Patent number: 7169775
    Abstract: Amino methyl imidazoles of Formula I are provided: wherein R, R1, R2, R3, R4, R5, and R6 are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. Additionally, this invention provides labeled amino methyl imidazoles compounds, which are useful as probes for the localization of C5a receptors.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: January 30, 2007
    Assignee: Neurogen Corporation
    Inventors: Andrew Thurkauf, He Zhao, Suoming Zhang, Yang Gao
  • Publication number: 20070004711
    Abstract: The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections.
    Type: Application
    Filed: May 9, 2006
    Publication date: January 4, 2007
    Inventors: Suoming Zhang, Avinash Phadke, Cuixian Liu, Xiangzhu Wang, Jesse Quinn, Dawei Chen, Venkat Gadhachanda, Shouming Li, Milind Deshpande
  • Publication number: 20060199823
    Abstract: Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Application
    Filed: March 24, 2006
    Publication date: September 7, 2006
    Applicant: Neurogen Corporation
    Inventors: Ping Ge, Raymond Horvath, Lu Zhang, Yasuchika Yamaguchi, Bernd Kaiser, Xuechun Zhang, Suoming Zhang, He Zhao
  • Publication number: 20060166906
    Abstract: Compounds having formula (I) are useful for treating bacterial infections while avoiding the concomitant liability of gastrointestinal intolerance. Compositions containing the compounds and methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: October 16, 2001
    Publication date: July 27, 2006
    Inventors: Zhenkun Ma, Ly Phan, Richard Clark, Suoming Zhang, Stevan Djuric
  • Publication number: 20060154917
    Abstract: (Heterocycloalkyl)methyl azole derivatives of Formula (I) are provided: Formula I wherein A is oxygen, sulfur, or NR; J and K and each L are independently oxygen, sulfur, NH, or CH2; and the remaining variables are defined herein. Such compounds are modulators of C5a receptors, and preferably bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. Also provided herein are pharmaceutical compositions comprising such compounds, as well as methods for using such compounds in treating a variety of inflammatory and immune system disorders.
    Type: Application
    Filed: June 30, 2004
    Publication date: July 13, 2006
    Applicant: Neurogen Corporation
    Inventors: Suoming Zhang, He Zhao, Yang Gao, Andrew Thurkauf, George Maynard, Bertrand Chenard, Robert Ohliger, John Peterson
  • Patent number: 6946446
    Abstract: The invention relates to novel methods for using macrolide anti-infective agents. The macrolide anti-infective agents demonstrate antibacterial activity against multi-drug resistant strains of bacteria and, in particular, methicillin-resistant Staphylococcus aureus (MRSA). Methods for inhibiting the activity of multi-drug resistant bacterial organisms and methods for treating a bacterial infection caused by such organisms are described herein.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: September 20, 2005
    Assignee: Abbott Laboratories
    Inventors: Zhenkun Ma, Peter Nemoto, Suoming Zhang, Hong Yong, Yat Sun Or
  • Publication number: 20050113379
    Abstract: Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Application
    Filed: September 3, 2004
    Publication date: May 26, 2005
    Inventors: Ping Ge, Raymond Horvath, Lu Yan Zhang, Yasuchika Yamaguchi, Bernd Kaiser, Xuechun Zhang, Suoming Zhang, He Zhao, Stanly John, Neil Moorcroft, Greg Shutske
  • Publication number: 20040116424
    Abstract: The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula 1
    Type: Application
    Filed: March 28, 2003
    Publication date: June 17, 2004
    Applicant: Neurogen Corporation
    Inventors: George P. Luke, George D. Maynard, Scott Mitchell, Andrew Thurkauf, Linghong Xie, LuYan Zhang, Suoming Zhang, He Zhao, Bertrand L. Chenard, Yang Gao, Bingsong Han, Xiao Shu He
  • Publication number: 20040082577
    Abstract: Amino methyl imidazoles of Formula I are provided: 1
    Type: Application
    Filed: August 21, 2003
    Publication date: April 29, 2004
    Applicant: Neurogen Corporation
    Inventors: Andrew Thurkauf, He Zhao, Suoming Zhang, Yang Gao
  • Patent number: 6667338
    Abstract: Compounds of formula (I) and formula (II) or therapeutically acceptable salts or prodrugs thereof are useful as antibacterial agents. Methods to make the compounds, compositions containing the compounds, and methods of treatment using the compounds are also disclosed.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: December 23, 2003
    Assignee: Abbott Laboratories
    Inventors: Zhenkun Ma, Ly Tam Phan, Suoming Zhang, Stevan W. Djuric
  • Publication number: 20020193320
    Abstract: A compound having the formula selected from the group consisting of 1
    Type: Application
    Filed: May 3, 2000
    Publication date: December 19, 2002
    Inventors: Zhenkun Ma, Yat Sun Or, Ly Tam Phan, Suoming Zhang, Richard F. Clark
  • Publication number: 20020142973
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: January 16, 2002
    Publication date: October 3, 2002
    Inventors: Zhenkun Ma, Ly Tam Phan, Suoming Zhang, Stevan W. Djuric
  • Publication number: 20020132782
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: January 18, 2001
    Publication date: September 19, 2002
    Inventors: Zhenkun Ma, Ly Tam Phan, Suoming Zhang, Stevan Djuric
  • Patent number: 6355620
    Abstract: A compound having the formula selected from the group consisting of a compound of formula I a compound of formula II a compound of formula III as well as and pharmaceutically acceptable salts, esters, solvates, metabolites, and prodrugs thereof, are useful in treating bacterial infections. Also provided are pharmaceutically acceptible compositions, methods of treating bacterial infections, and processes for the preparation of the compounds.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: March 12, 2002
    Assignee: Abbott Laboratories
    Inventors: Zhenkun Ma, Yat Sun Or, Ly Tam Phan, Suoming Zhang, Richard F. Clark